AU2015316801B2 - Macrocyclic LRRK2 kinase inhibitors - Google Patents
Macrocyclic LRRK2 kinase inhibitors Download PDFInfo
- Publication number
- AU2015316801B2 AU2015316801B2 AU2015316801A AU2015316801A AU2015316801B2 AU 2015316801 B2 AU2015316801 B2 AU 2015316801B2 AU 2015316801 A AU2015316801 A AU 2015316801A AU 2015316801 A AU2015316801 A AU 2015316801A AU 2015316801 B2 AU2015316801 B2 AU 2015316801B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- het
- halo
- optionally
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCC(**)C1NC(*)CC*11CCCC1 Chemical compound CCC(**)C1NC(*)CC*11CCCC1 0.000 description 13
- RYRDEHUYNYQVOQ-UHFFFAOYSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4OCCN(CC3)CCC3Nc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4OCCN(CC3)CCC3Nc1c2 RYRDEHUYNYQVOQ-UHFFFAOYSA-N 0.000 description 2
- PFAUHGVTBUAZFV-UHFFFAOYSA-N Fc1ccc2NCCN(CCC3)C3CCNc(cc[n]3nc4)nc3c4-c1c2 Chemical compound Fc1ccc2NCCN(CCC3)C3CCNc(cc[n]3nc4)nc3c4-c1c2 PFAUHGVTBUAZFV-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- KRBHTTDPDIGTHM-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1N(CCO[Si+](C)(C)C(C)(C)C)CCC1)c(cc[n]1nc2)nc1c2-c(cc(cc1)NS(c(cccc2)c2[N+]([O-])=O)(=O)=O)c1F)=O Chemical compound CC(C)(C)OC(N(CCC1N(CCO[Si+](C)(C)C(C)(C)C)CCC1)c(cc[n]1nc2)nc1c2-c(cc(cc1)NS(c(cccc2)c2[N+]([O-])=O)(=O)=O)c1F)=O KRBHTTDPDIGTHM-UHFFFAOYSA-N 0.000 description 1
- XMBUHAIRGSIDTQ-UHFFFAOYSA-N CC(C)(C)[SH-](c1ccccc1)(c1ccccc1)OCC1NCCC1 Chemical compound CC(C)(C)[SH-](c1ccccc1)(c1ccccc1)OCC1NCCC1 XMBUHAIRGSIDTQ-UHFFFAOYSA-N 0.000 description 1
- WEVLHAUFONQFER-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OC1CCNCC1 Chemical compound CC(C)(C)[Si+](C)(C)OC1CCNCC1 WEVLHAUFONQFER-UHFFFAOYSA-N 0.000 description 1
- PAKJHFGGLADPIT-ATYDEFKCSA-N CC(C)(CC(CCNC1=NC2=C3C(C4)C4N2C=C1)[C@@H](C1)NOc(cc2)cc3c2F)C1C1CC1 Chemical compound CC(C)(CC(CCNC1=NC2=C3C(C4)C4N2C=C1)[C@@H](C1)NOc(cc2)cc3c2F)C1C1CC1 PAKJHFGGLADPIT-ATYDEFKCSA-N 0.000 description 1
- LOGFPJYFGZLNJV-GBAXHLBXSA-N CC(C)(CC=C1CCNc2nc3c-4cc(C)[n]3cc2)C(CC=C)C[C@H]1[IH]Oc(cc1)cc-4c1F Chemical compound CC(C)(CC=C1CCNc2nc3c-4cc(C)[n]3cc2)C(CC=C)C[C@H]1[IH]Oc(cc1)cc-4c1F LOGFPJYFGZLNJV-GBAXHLBXSA-N 0.000 description 1
- VNOGDDMDWQPUPJ-HSZRJFAPSA-N CC(C)[C@@H]1NCCN(CCN(C)C(C=CN2C=C=C3)=NC2=C3c2cc(ON=C)ccc2F)C1 Chemical compound CC(C)[C@@H]1NCCN(CCN(C)C(C=CN2C=C=C3)=NC2=C3c2cc(ON=C)ccc2F)C1 VNOGDDMDWQPUPJ-HSZRJFAPSA-N 0.000 description 1
- SUMUZLGGTURAOO-UHFFFAOYSA-N CN(C(CC1)CN1CCO1)c(cc[n]2nc3)nc2c3-c2cc1ccc2F Chemical compound CN(C(CC1)CN1CCO1)c(cc[n]2nc3)nc2c3-c2cc1ccc2F SUMUZLGGTURAOO-UHFFFAOYSA-N 0.000 description 1
- HFPXFTNSXJGQRU-UHFFFAOYSA-N CN(CCC(CCCC1)C1OC(C1)C=C2)c(cc[n]3nc4)nc3c4C1=C2F Chemical compound CN(CCC(CCCC1)C1OC(C1)C=C2)c(cc[n]3nc4)nc3c4C1=C2F HFPXFTNSXJGQRU-UHFFFAOYSA-N 0.000 description 1
- VUIPZLGFICTMQQ-UHFFFAOYSA-N CS(OCCNc(cc1)n[n]2c1ncc2Br)(=O)=O Chemical compound CS(OCCNc(cc1)n[n]2c1ncc2Br)(=O)=O VUIPZLGFICTMQQ-UHFFFAOYSA-N 0.000 description 1
- OWJSGAJHBBRIAW-KSFYIVLOSA-N C[C@](CCNC1)(C[C@@H]1Oc(cc1)c2)CCNc(cc[n]3cc4)nc3c4-c2c1F Chemical compound C[C@](CCNC1)(C[C@@H]1Oc(cc1)c2)CCNc(cc[n]3cc4)nc3c4-c2c1F OWJSGAJHBBRIAW-KSFYIVLOSA-N 0.000 description 1
- UQHASBXLPFVIHP-UHFFFAOYSA-N C[N]1(C)CCCC1 Chemical compound C[N]1(C)CCCC1 UQHASBXLPFVIHP-UHFFFAOYSA-N 0.000 description 1
- IEDYMGDFQSIRPU-QRWMCTBCSA-N Fc(cc1)c2-c(cc[n]3cc4)c3nc4NCCC(CCCC3)CC[C@@H]3C#[N+][O-]c1c2 Chemical compound Fc(cc1)c2-c(cc[n]3cc4)c3nc4NCCC(CCCC3)CC[C@@H]3C#[N+][O-]c1c2 IEDYMGDFQSIRPU-QRWMCTBCSA-N 0.000 description 1
- BHVIDIBBALJGIR-UHFFFAOYSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CC3)CCC3Nc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CC3)CCC3Nc1c2 BHVIDIBBALJGIR-UHFFFAOYSA-N 0.000 description 1
- GOUWYTASGRZKFS-UHFFFAOYSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CC3)CCC3Oc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CC3)CCC3Oc1c2 GOUWYTASGRZKFS-UHFFFAOYSA-N 0.000 description 1
- RIHFAEDNUBECRD-AWEZNQCLSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CCC3)[C@@H]3CNc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CCC3)[C@@H]3CNc1c2 RIHFAEDNUBECRD-AWEZNQCLSA-N 0.000 description 1
- SWMUPDNPQBLHII-CQSZACIVSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CCNC3)C[C@@H]3Oc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4NCCN(CCNC3)C[C@@H]3Oc1c2 SWMUPDNPQBLHII-CQSZACIVSA-N 0.000 description 1
- VUCDMEYVVSMOMB-HNNXBMFYSA-N Fc(cc1)c2-c(cn[n]3cc4)c3nc4OCCCN(CCC3)[C@@H]3CNc1c2 Chemical compound Fc(cc1)c2-c(cn[n]3cc4)c3nc4OCCCN(CCC3)[C@@H]3CNc1c2 VUCDMEYVVSMOMB-HNNXBMFYSA-N 0.000 description 1
- KLPLGZLHKCMPSU-UHFFFAOYSA-N Fc(ccc(OC1)c2)c2C(C=C=CN2C=C3)=C2N=C3NCCN2C1C=CCC2 Chemical compound Fc(ccc(OC1)c2)c2C(C=C=CN2C=C3)=C2N=C3NCCN2C1C=CCC2 KLPLGZLHKCMPSU-UHFFFAOYSA-N 0.000 description 1
- XKAYDIDATNLAHX-GFCCVEGCSA-N Fc1ccc2OCCN(CC3)C[C@@H]3NC(C=C[I]3N=C4)=NC3=C4c1c2 Chemical compound Fc1ccc2OCCN(CC3)C[C@@H]3NC(C=C[I]3N=C4)=NC3=C4c1c2 XKAYDIDATNLAHX-GFCCVEGCSA-N 0.000 description 1
- JADSOIFVJYHGGX-CYBMUJFWSA-N Fc1ccc2OC[C@@H](CNCC3)N3CCNc(cc[n]3nc4)nc3c4-c1c2 Chemical compound Fc1ccc2OC[C@@H](CNCC3)N3CCNc(cc[n]3nc4)nc3c4-c1c2 JADSOIFVJYHGGX-CYBMUJFWSA-N 0.000 description 1
- NGCIVOPHDCSTIP-AWEZNQCLSA-N Fc1ccc2OC[C@H](CCC3)N3CCCNc(cc[n]3nc4)nc3c4-c1c2 Chemical compound Fc1ccc2OC[C@H](CCC3)N3CCCNc(cc[n]3nc4)nc3c4-c1c2 NGCIVOPHDCSTIP-AWEZNQCLSA-N 0.000 description 1
- QTEZWBYKEUXIOK-IBGZPJMESA-N [O-][N+](c(cccc1)c1S(N(C[C@H](CCC1)N1CCCOc1nc2c-3cn[n]2cc1)c(cc1)cc-3c1F)(=O)=O)=O Chemical compound [O-][N+](c(cccc1)c1S(N(C[C@H](CCC1)N1CCCOc1nc2c-3cn[n]2cc1)c(cc1)cc-3c1F)(=O)=O)=O QTEZWBYKEUXIOK-IBGZPJMESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279.0 | 2014-09-17 | ||
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015316801A1 AU2015316801A1 (en) | 2017-04-27 |
| AU2015316801B2 true AU2015316801B2 (en) | 2019-03-07 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015316801A Ceased AU2015316801B2 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic LRRK2 kinase inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T4 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| CA3168814A1 (en) * | 2020-01-31 | 2021-08-05 | Oncodesign S.A. | Macrocyclic rip2-kinase inhibitors |
| MX2022013861A (es) | 2020-05-06 | 2023-02-22 | Servier Lab | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
| WO2022194976A1 (en) | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
| US20240417378A1 (en) * | 2021-10-11 | 2024-12-19 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| WO2023073013A1 (en) * | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
| WO2024218290A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| AR132487A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013046029A1 (en) * | 2011-09-30 | 2013-04-04 | Ipsen Pharma S.A.S. | Macrocyclic lrrk2 kinase inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| ES2166786T3 (es) | 1993-10-01 | 2002-05-01 | Astrazeneca Ab | Procedimiento i. |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| AU2002226674B2 (en) | 2000-12-28 | 2007-03-22 | Ono Pharmaceutical Co., Ltd. | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2006045392A2 (en) | 2004-10-21 | 2006-05-04 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| CN101360751B (zh) | 2005-11-16 | 2011-09-14 | S*Bio私人有限公司 | 氧连接的嘧啶衍生物 |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| BR122019024201B1 (pt) * | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| MX347765B (es) * | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
-
2015
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 PL PL15766801T patent/PL3194405T4/pl unknown
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013046029A1 (en) * | 2011-09-30 | 2013-04-04 | Ipsen Pharma S.A.S. | Macrocyclic lrrk2 kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201625639A (zh) | 2016-07-16 |
| IL251054B (en) | 2019-03-31 |
| EP3194405B1 (en) | 2018-12-26 |
| AU2015316801A1 (en) | 2017-04-27 |
| JP2017529365A (ja) | 2017-10-05 |
| PL3194405T3 (pl) | 2019-07-31 |
| EA032838B1 (ru) | 2019-07-31 |
| US10377772B2 (en) | 2019-08-13 |
| SG11201701936WA (en) | 2017-04-27 |
| ES2717510T3 (es) | 2019-06-21 |
| HUE043972T2 (hu) | 2019-09-30 |
| EP3194405A1 (en) | 2017-07-26 |
| CA2960777A1 (en) | 2016-03-24 |
| EA201790626A1 (ru) | 2017-07-31 |
| DK3194405T3 (en) | 2019-04-15 |
| CN107108641A (zh) | 2017-08-29 |
| MX2017003470A (es) | 2017-08-07 |
| TR201904514T4 (tr) | 2019-04-22 |
| ZA201701841B (en) | 2019-08-28 |
| BR112017005299A2 (pt) | 2017-12-12 |
| IL251054A0 (en) | 2017-04-30 |
| WO2016042089A1 (en) | 2016-03-24 |
| PL3194405T4 (pl) | 2019-07-31 |
| KR20170048599A (ko) | 2017-05-08 |
| US20170240565A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3194405T3 (en) | MACROCYCLIC LRRK2 KINase INHIBITORS | |
| AU2012314035B2 (en) | Macrocyclic LRRK2 kinase inhibitors | |
| AU2012314376B2 (en) | Macrocyclic FLT3 kinase inhibitors | |
| DK2970333T3 (en) | MACROCYCLIC LRRK2 KINase INHIBITORS | |
| WO2014140313A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| EP3481824B1 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| WO2016146651A1 (en) | Macrocyclic activin-like receptor kinase inhibitors | |
| AU2015316799B2 (en) | Macrocyclic RIP2 kinase inhibitors | |
| EP2760867B1 (en) | Macrocyclic flt3 kinase inhibitors | |
| US20210267994A1 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| HK1240586A1 (zh) | 大环lrrk2激酶抑制剂 | |
| HK1219481B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| HK1199838B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| EP2968326A1 (en) | Macrocyclic salt-inducible kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ONCODESIGN S.A. Free format text: FORMER APPLICANT(S): ONCODESIGN S.A.; IPSEN PHARMA S.A.S. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |